Stella Pharma Corporation (4888.T)
Tokyo · JPY · Healthcare · Biotechnology
¥430 (+4.62%) as of
Key statistics
- Market cap
- 15.49B
- EPS (TTM)
- -25.46
- Dividend yield
- 0.00%
- 52-week range
- 200.00 – 995.00
- Beta
- 0.33
- Revenue (TTM)
- 323M
- Profit margin
- -263.78%
- Volume
- 386.00k
About Stella Pharma Corporation
Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Osaka, Japan
- Employees
- 47
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.